Navigation Links
Selecta II Glaucoma Laser System

ProductsSelecta II Glaucoma Laser System
Company Lumenis Inc.
Item Selecta II Glaucoma Laser System
Features Q-switch produces short pulses of low energy laser light. Selectively targets pigmented cells, increasing fluid outflow. Eliminates burns that scar trabecular meshwork. Economical and efficient, treatment is performed in the physician's office. Provides economic benefits for the patient and physician.
Description The Selecta II Glaucoma Laser System features a patented technique for performing trabeculoplasty in patients with open-angle glaucoma. It selectively targets pigmented cells and increases fluid output, lowering intraocular pressure. The Selecta II is equipped with a Q-switch that produces a 3-nanosecond high-energy beam of light, which induces the same cell replacement mechanism as traditional argon laser therapy (ALT), but without the burn. The short pulse of the laser does not allow time for heat to spread to other cells.
Info Lumenis Inc.
Customer Service: 877-lumenis
Web site: http://www.lumenis.com

Related medicine products :

1. Selecta II Glaucoma Laser System
2. Selecta Duet
3. Selecta 1064 nm Nd:YAG Base Platform
4. Selecta Duo Photocoagulator Combination Laser
5. Selecta Trio Photocoagulator and SLT Combination Laser
6. Baerveldt Glaucoma Implant
7. Baerveldt Pars Plan Glaucoma Implant
8. Ahmed Glaucoma Valve
9. Ahmed Glaucoma Valve Flexible Plate
10. Ahmed Glaucoma Valve (small size)
11. Ahmed Glaucoma Valve with Pars Plana Clip
The inventory system designed for Wholesale Distributors and centralized distribution centers for Optical chains.
...Ordering/Dispensing has gained recognition as the ... lens ordering system. It enables opticians to pla...g SDS electronic communications technology. When u...r 3D frame tracers, lens shapes are automatically ...
... is a complete practice and business management so...ts, opticians and ophthalmologists- It is designed...ally rich and intuitive windows interface with a f...- The multi-user version of this practice and Busi...
The K-4500 automated hematology analyzer offers fast reliable test results of 18-parameter plus 3-histograms, valuable for effective diagnosis.
Medicine Products:
(Date:12/2/2008)...image-guided treatment is a safe and precise metho...om the body, according to the first report on "sel...licted foreign body insertion in adolescents. The ...ting of the Radiological Society of North America ... to be the first to detect self-embedding disorder...
(Date:12/2/2008)...ewswire/ -- Research scientists using a,novel, ha...I) have found that,chronic stroke patients can be...day at the annual meeting of the Radiological Soci...udy using fMRI to map the brain in order to track,...at the brain has the ability to regain function th...
(Date:12/2/2008)...c. 1 diaDexus, Inc. today,announc...ated format of the,PLAC Test for Lp-PLA2. This au...nning on a wide range of clinical chemistry analyz... Administration (FDA) in December 2007. diaDexus a... PLAC Test to Europe. , The PLAC Test is th...
(Date:12/2/2008)...re/ -- At a symposium today hosted by Johns,Hopk...nce researchers presented,the latest research in ...g the,science into technology to improve lives. H...sented evidence that cognitive intervention develo...ty, the brain,s ability to,reorganize itself thro...
Breaking Medicine News(10 mins):Health News:Radiologists diagnose and treat self-embedding disorder in teens 2Health News:Robotic Technology Improves Stroke Rehabilitation 2Health News:Robotic Technology Improves Stroke Rehabilitation 3Health News:diaDexus Receives CE Mark Certification for the PLAC(R) Test 2Health News:Posit Science Invited to Speak at Johns Hopkins University About Cutting Edge Cognitive Training Interventions 2
...ssociation between the level of sex hormones and a...eptors for the female hormones estrogen and proges...eptors are the eyes and ears of the cells, receivi... hormones. Estrogen and progesterone stimulate gro...
...acupuncture can help those suffering from arthriti...rrent multi-location trial included 570 patients a...articipants were placed in three groups. One hundr...ure, 191 underwent sham acupuncture, and 189 follo...
...ns are currently performed among the diabetic popu... blood vessels in the retinas of about 900 diabeti... before age 30. All were followed for 20 years to ...ight relate to subsequent need for an amputation. ...
... of countries where iodine deficiency is a public ... on a new global report on iodine status.// The si...ed well. The number of countries where iodine defi...reduced to 54 in 2003, from 110 in 1993. "Iodine d...
Other Medicine News:Health News:WHO hopes to wipe away Iodine deficiency diseases by 2005 2
(Date:12/2/2008)...ll., Dec. 2 Horizon Therapeutics, ... today announced that two pivotal,Phase 3 trials ...ate, HZT-501,met all primary endpoints. HZT-501,...uct containing ibuprofen and famotidine, demonstra...incidence of non-steroidal,anti-inflammatory drug...
(Date:12/1/2008)..., Dec. 1 TargeGen has announced th...rom a multi-center, US-based clinical,trial of TG...been scheduled at,the 2008 American Society of He...presentation are as follows:, Title: ...ailable, JAK2-Selective In...
(Date:12/1/2008)...tinence is still the best policy , , ROCHE...ew study from Mayo Clinic finds the use of the dru...olic hepatitis, an acute inflammation of the liver...esults of the study are published in the December ...rnal.org/ ). , , VIDEO ALERT: Additional a...
(Date:12/1/2008)..., Dec. 1 Vical Incorpora...of a $1.0 million milestone payment from Merck &am...f a Phase I clinical trial of an investigational p...ccine is based on Vical,s DNA gene delivery techno...ptase (hTERT). hTERT is the subject of separate li...
Breaking Medicine Technology:Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 2Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 4Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 2Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 3Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial 2Pharmion to Present Clinical Data on Key Hematology Products at American Society of Hematology 28ASH 29 Annual Meeting 7707 1Pharmion to Present Clinical Data on Key Hematology Products at American Society of Hematology 28ASH 29 Annual Meeting 7707 2Pharmion to Present Clinical Data on Key Hematology Products at American Society of Hematology 28ASH 29 Annual Meeting 7707 3Pharmion to Present Clinical Data on Key Hematology Products at American Society of Hematology 28ASH 29 Annual Meeting 7707 4Pharmion to Present Clinical Data on Key Hematology Products at American Society of Hematology 28ASH 29 Annual Meeting 7707 5Pharmion to Present Clinical Data on Key Hematology Products at American Society of Hematology 28ASH 29 Annual Meeting 7707 6Pharmion to Present Clinical Data on Key Hematology Products at American Society of Hematology 28ASH 29 Annual Meeting 7707 7Pharmion to Present Clinical Data on Key Hematology Products at American Society of Hematology 28ASH 29 Annual Meeting 7707 8Pharmion to Present Clinical Data on Key Hematology Products at American Society of Hematology 28ASH 29 Annual Meeting 7707 9Pharmion to Present Clinical Data on Key Hematology Products at American Society of Hematology 28ASH 29 Annual Meeting 7707 10Clarient CEO Andrews to Participate in Panel Discussion at the RBC Capital Markets 2007 Healthcare Conference 7705 1Clarient CEO Andrews to Participate in Panel Discussion at the RBC Capital Markets 2007 Healthcare Conference 7705 2Memory Pharmaceuticals Receives Nasdaq Notification Related to Minimum Bid Price 7703 1Memory Pharmaceuticals Receives Nasdaq Notification Related to Minimum Bid Price 7703 2Memory Pharmaceuticals Receives Nasdaq Notification Related to Minimum Bid Price 7703 3Lilly Showcases Pipeline Opportunities to Wall Street Sets 2008 Financial Guidance and Outlines Transformation Strategy 7701 1Lilly Showcases Pipeline Opportunities to Wall Street Sets 2008 Financial Guidance and Outlines Transformation Strategy 7701 2Lilly Showcases Pipeline Opportunities to Wall Street Sets 2008 Financial Guidance and Outlines Transformation Strategy 7701 3Lilly Showcases Pipeline Opportunities to Wall Street Sets 2008 Financial Guidance and Outlines Transformation Strategy 7701 4Lilly Showcases Pipeline Opportunities to Wall Street Sets 2008 Financial Guidance and Outlines Transformation Strategy 7701 5Lilly Showcases Pipeline Opportunities to Wall Street Sets 2008 Financial Guidance and Outlines Transformation Strategy 7701 6Lilly Showcases Pipeline Opportunities to Wall Street Sets 2008 Financial Guidance and Outlines Transformation Strategy 7701 7Lilly Showcases Pipeline Opportunities to Wall Street Sets 2008 Financial Guidance and Outlines Transformation Strategy 7701 8Lilly Showcases Pipeline Opportunities to Wall Street Sets 2008 Financial Guidance and Outlines Transformation Strategy 7701 9Lilly Showcases Pipeline Opportunities to Wall Street Sets 2008 Financial Guidance and Outlines Transformation Strategy 7701 10Lilly Showcases Pipeline Opportunities to Wall Street Sets 2008 Financial Guidance and Outlines Transformation Strategy 7701 11Lilly Showcases Pipeline Opportunities to Wall Street Sets 2008 Financial Guidance and Outlines Transformation Strategy 7701 12Lilly Showcases Pipeline Opportunities to Wall Street Sets 2008 Financial Guidance and Outlines Transformation Strategy 7701 13Lilly Showcases Pipeline Opportunities to Wall Street Sets 2008 Financial Guidance and Outlines Transformation Strategy 7701 14
... - TransPharma Medical,Ltd., a specialty pharmaceu...rcialization of drug products utilizing a propriet...nnounced today,promising results of its phase I cl...okinetic profile of its ViaDerm-hPTH (1-34),produc... repeated dose application, parallel group study w...
... to Show That Extended,Thromboprophylaxis Reduces ...atistically Significant 44% , PARIS, July 8, 2007 ...today the results of the EXCLAIM (EXtended CLinica...dy, which showed,the benefit of extended prophylax...bility by demonstrating the superiority of 5 weeks...
Other Medicine Technology:TransPharma Medical Announces Positive Results of Phase I Clinical,Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis,Treatment 2TransPharma Medical Announces Positive Results of Phase I Clinical,Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis,Treatment 3New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 2New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 3New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 4New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 5New Study Shows That Extending Prophylaxis With Clexane / Lovenox,(enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10,Days for Reducing the Risk of Venous Thromboembolism (VTE) in,Acutely ill Medical Patients With Reduced Mobility 6